Enorama Pharma AB OMXSTO:ERMA:
POSTPONES PUBLICATION OF ITS 2025 YEAR-END REPORT
Enorama Pharma Postpones Its 2025 Year-End Report
Earlier from Enorama Pharma Ab
- Enorama Pharma Subsidiary Intends To Appeal FDA's Refuse-To-File Decision
- Bulletin from the extraordinary general meeting in Enorama Pharma Ab (publ)
- Enorama Pharma Q3 Operating Loss Widens To SEK 12.3 Mln